Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus empagliflozin for coronary plaque progression after acute coronary syndrome in type 2 diabetes
ACTRN12623000661673Phase 2Terminated
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis comparing Semaglutide with Empagliflozin (2 arms). Primary endpoint: Progression rates of low attenuation plaque. Started Apr 2024; status: terminated.
02
Drugs
semaglutideempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12623000661673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000661673.